AN2 Therapeutics, Inc.
ANTX
$4.27
-$0.45-9.53%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 6.87% | -44.74% | 39.32% | -41.57% | 40.99% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 117.46% | -65.27% | 5.92% | 32.23% | 3.59% |
| Change in Net Operating Assets | -8.25% | 184.20% | -79.61% | -252.41% | 340.37% |
| Cash from Operations | 17.87% | 16.11% | 28.47% | -101.48% | 56.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 17.41% | 4.73% | -36.54% | 233.62% | -136.75% |
| Cash from Investing | 17.41% | 4.73% | -36.54% | 233.62% | -136.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -- | -100.00% | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.00% | -- | -100.00% | -- | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 993.09% | 87.71% | -29.21% | 88.76% | -280.45% |